L-arginine

Generic Name: L-arginine

Brand Names: Clinimix 2.75/5

Drug Type: Small Molecule

CAS Number: 74-79-3

Clinical Trials

L-Arginine and Sickle Cell Disease

Phase 3

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: L-arginine
Drug: Placebo

First Posted Date: 2010-06-11

Last Posted Date: 2010-06-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 40

Registration Number: NCT01142219

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

L-Arginine Supplementation With or Without Enzyme Inhibitors Treating Erectile Function of Prostate Cancer Survivors

Phase 2

Completed

Conditions: Male Erectile Disorder
Prostate Cancer
Radiation Toxicity

Interventions: Drug: Oral L-Arginine
Other: Placebo

First Posted Date: 2010-04-16

Last Posted Date: 2021-09-28

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 140

Registration Number: NCT01105130

Locations: 🇺🇸
W F Baptist Health, Winston-Salem, North Carolina, United States

Directed Immuno Nutrition by L-arginine for Critically Ill Patients

Phase 4

Completed

Conditions: Critically Ill

Interventions: Drug: L-arginine
Drug: placebo

First Posted Date: 2009-12-24

Last Posted Date: 2013-09-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 30

Registration Number: NCT01038622

Locations: 🇫🇷
Medical Intensive Care Unit, Pompidou Hospital, Paris, France

L-arginine Effects on Chronic Hypertension in Pregnancy

Phase 3

Completed

Conditions: Hypertension in Pregnancy

Interventions: Other: placebo
Drug: L-arginine

First Posted Date: 2009-09-10

Last Posted Date: 2010-01-20

Lead Sponsor: University of Modena and Reggio Emilia

Target Recruit Count: 80

Registration Number: NCT00974714

Locations: 🇮🇹
University of Modena and Reggio Emilia, Modena, Mo, Italy

Prevention of Type 2 Diabetes Mellitus by L-Arginine in Patients With Metabolic Syndrome

Phase 3

Completed

Conditions: Metabolic Syndrome
Impaired Glucose Tolerance
Insulin Resistance
Endothelial Dysfunction

Interventions: Drug: Placebo
Drug: L-arginine

First Posted Date: 2009-06-10

Last Posted Date: 2009-06-10

Lead Sponsor: IRCCS San Raffaele

Target Recruit Count: 142

Registration Number: NCT00917449

Locations: 🇮🇹
Scientific Institute San Raffaele, Milan, Italy

Heme Oxygenase (HO) Activity and Adenosine Induced Vasodilation

Phase 4

Terminated

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: L-arginine + heme arginate
Drug: Heme arginate + L-arginine

First Posted Date: 2009-03-06

Last Posted Date: 2011-08-11

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 6

Registration Number: NCT00856817

Locations: 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands

Endothelial Function in Human Arteries

Early Phase 1

Completed

Conditions: Endothelial Dysfunction

Interventions: Drug: L-arginine

First Posted Date: 2009-02-20

Last Posted Date: 2017-03-07

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 25

Registration Number: NCT00848302

Effect of Chronic Supplementation of L-arginine in the Muscular Performance

Phase 4

Terminated

Conditions: Muscular Fatigue

Interventions: Drug: L-arginine aspartate (Targifor)
Drug: Placebo L-arginine aspartate (Targifor)

First Posted Date: 2008-11-05

Last Posted Date: 2011-03-16

Lead Sponsor: Sanofi

Target Recruit Count: 36

Registration Number: NCT00785811

Locations: 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil

L-Arginine and Erectile Dysfunction

Phase 4

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Placebo
Drug: L-arginine

First Posted Date: 2008-10-22

Last Posted Date: 2008-10-22

Lead Sponsor: Hannover Medical School

Target Recruit Count: 57

Registration Number: NCT00777075

Locations: 🇩🇪
Institute of Clinical Pharmacology, Hannover Medical School, Hannover, Lower Saxony, Germany

L-arginine in Treatment as Usual in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia

Interventions: Drug: L-Arginine

First Posted Date: 2008-07-18

Last Posted Date: 2017-09-05

Lead Sponsor: University of Alberta

Target Recruit Count: 13

Registration Number: NCT00718510

Locations: 🇨🇦
Alberta Hospital Edmonton, Edmonton, Alberta, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy